1. Optimizing the trade-off between learning and doing in a pandemic;Angus;JAMA,2020
2. FDA . Coronavirus (COVID-19) update: FDA Authorizes first oral antiviral for treatment of COVID-19, 2021. Available: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 [Accessed 5 Oct 2022].
3. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
4. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study;Nyberg;Lancet,2022
5. Pfizer Inc . Pfizer Announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death | pfizer, 2021. Available: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results [Accessed 14 Dec 2021].